Life Beyond Provenge: Dendreon Plans To Move First Small Molecule Into The Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
While Dendreon awaits data to complete the prostate cancer vaccine’s BLA, other candidates progress.
You may also be interested in...
House Panel Denies Members' Request To Investigate Provenge Advisory Committee
Bipartisan group looking to investigate conflict of interest at an FDA advisory committee on Provenge were stopped in their tracks by a letter from Energy & Commerce Committee leaders.
Provenge Review In 2008 Hinges On IMPACT Interim Analysis
FDA will accept positive interim analysis of survival from the Phase III trial for registration of the therapeutic cancer vaccine, Dendreon confirms.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.